Stockreport

Royalty Pharma promises $500M to Teva for advancing vitiligo treatment [Seeking Alpha]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Royalty Pharma will provide up to $500 million, starting with $75 million to co-fund a Phase 2b vitiligo trial planned Newsletters for Every Investor Get daily, sec [Read more]